Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 10 min ago
Peer-reviewedCC BY-NC-ND 4.0NPJ Vaccines

Post-exposure vaccination with an adjuvanted protein subunit vaccine, but not BCG, protects mice and guinea pigs against M. tuberculosis

  • Joshua S. Woodworth1,2
  • Claus Aagaard1
  • Francisco J. Salguero3
  • Laura Hunter3
  • Thomas Lindenstrøm1,2
  • Simon Clark3
  • Rasmus Mortensen1,2
  1. 1Department of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark
  2. 2Novo Nordisk Foundation Initiative for Vaccines and Immunity, NIVI Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
  3. 3Countermeasure Development, Evaluation and Preparedness (CDEP), United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, UK
Read full textPDFDOICite

Abstract

Tuberculosis (TB) remains a global health priority and vaccines targeting populations with prior Mycobacterium tuberculosis (Mtb) exposure are predicted to most rapidly impact epidemic control. Paradoxically, while efficacy trials are primarily targeting previously Mtb-exposed populations, preclinical testing largely relies on Mtb-naïve animal models. We introduce two post-exposure models, a murine reinfection model and a previously unreported guinea pig reactivation model, and evaluate the efficacy of the adjuvanted protein subunit vaccine H107/CAF®01 compared to Bacillus Calmette-Guérin (BCG). Consistent with clinical and human population data, we demonstrate that BCG fails to confer significant protection in these post-Mtb-exposed settings. In contrast, H107/CAF®01 imprints distinct Th17 responses and provides robust and consistent protection, reducing both the bacterial burden and infection-associated tissue pathology. These findings support the development of H107 as a vaccine candidate in previously Mtb-exposed and infected populations and underscores the importance of evaluating TB vaccines in animal models that reflect prior exposure.

Related

  1. Muscle macrophage regenerative response after squalene-adjuvanted influenza vaccination is associated with type II-skewed response and is reduced with age
    Moataz Noureddine, Lauren A. Chang, Farah El Ayache +14
    NPJ VaccinesPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthPMC
  2. Maternal vaccination with capsular polysaccharide bioconjugates protects against murine Klebsiella pneumoniae neonatal sepsis
    Paeton L. Wantuch, Jessica Tung, Lloyd S. Robinson +5
    Science advancesPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref
  3. Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial
    Marc Bonten, Brandon Essink, Nikita Hanning +11
    Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of AmericaPeer-reviewedCC BY 4.0Full text2 citedEpidemiology & public healthPMC
  4. Vaccination Against HMGB1 Protects Mice from CCl₄-Induced Liver Injury, Inflammation, and Fibrosis.
    Qian Li, Hanchao Li, Yongwei Huo +6
    InflammationPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  5. Advancing Tuberculosis Vaccination: Immunological Insights and Emerging Strategies for Improved Protection.
    Zhicheng Zhang, Crystal Sanchez, Derek Baker +5
    VaccinesPeer-reviewedCC BYFull textInfectious diseaseEurope PMC

Cite

BibTeXRIS
BibTeX
@article{woodworth2026postexposure,
  title = {{Post-exposure vaccination with an adjuvanted protein subunit vaccine, but not BCG, protects mice and guinea pigs against M. tuberculosis}},
  author = {Joshua S. Woodworth and Claus Aagaard and Francisco J. Salguero and Laura Hunter and Thomas Lindenstrøm and Simon Clark and Rasmus Mortensen},
  journal = {NPJ Vaccines},
  year = {2026},
  month = jul,
  doi = {10.1038/s41541-026-01509-6},
  url = {https://doi.org/10.1038/s41541-026-01509-6},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Post-exposure vaccination with an adjuvanted protein subunit vaccine, but not BCG, protects mice and guinea pigs against M. tuberculosis
AU  - Joshua S. Woodworth
AU  - Claus Aagaard
AU  - Francisco J. Salguero
AU  - Laura Hunter
AU  - Thomas Lindenstrøm
AU  - Simon Clark
AU  - Rasmus Mortensen
PY  - 2026
DA  - 2026/07/08
JO  - NPJ Vaccines
DO  - 10.1038/s41541-026-01509-6
UR  - https://doi.org/10.1038/s41541-026-01509-6
AB  - Tuberculosis (TB) remains a global health priority and vaccines targeting populations with prior Mycobacterium tuberculosis (Mtb) exposure are predicted to most rapidly impact epidemic control. Paradoxically, while efficacy trials are primarily targeting previously Mtb-exposed populations, preclinical testing largely relies on Mtb-naïve animal models. We introduce two post-exposure models, a murine reinfection model and a previously unreported guinea pig reactivation model, and evaluate the efficacy of the adjuvanted protein subunit vaccine H107/CAF®01 compared to Bacillus Calmette-Guérin (BCG). Consistent with clinical and human population data, we demonstrate that BCG fails to confer significant protection in these post-Mtb-exposed settings. In contrast, H107/CAF®01 imprints distinct Th17 responses and provides robust and consistent protection, reducing both the bacterial burden and infection-associated tissue pathology. These findings support the development of H107 as a vaccine candidate in previously Mtb-exposed and infected populations and underscores the importance of evaluating TB vaccines in animal models that reflect prior exposure.
SN  - 2059-0105
ER  -